CervoMed Inc
CRVO7.790USD
-0.310-3.83%
收盘 09/19, 16:00（美东）报价延迟15分钟
72.08M总市值
亏损市盈率 TTM
关于 CervoMed Inc 公司
CervoMed Inc. 是一家临床阶段的生物技术公司，专注于开发与年龄相关的神经系统疾病的治疗方法。该公司专注于开发其主要候选药物 neflamapimod，这是一种口服小分子脑渗透剂，可抑制神经退行性疾病患者脑内神经元（神经细胞）中的 p38a。该公司的 neflamapimod 正处于临床开发阶段，作为一种用于治疗神经退行性疾病（如路易体痴呆和早期阿尔茨海默病）的疾病改良疗法。此外，临床前数据支持 neflamapimod 在卒中后康复中的潜在作用。neflamapimod 有可能治疗和改善突触功能障碍，这是路易体痴呆 (DLB) 和某些其他神经系统疾病的潜在疾病过程的可逆性方面。该公司正在进行的 RewinD-LB 试验正在对其进行评估，这是一项针对 DLB 患者的 2b 期研究。
公司简介
公司代码CRVO
公司名称CervoMed Inc
上市日期Nov 09, 2016
CEOMr. John J. Alam, M.D.
员工数量15
证券类型Ordinary Share
年结日Nov 09
公司地址20 Park Plaza, Suite 424
城市BOSTON
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编02116
电话16177444400
网址https://cervomed.com/
公司代码CRVO
上市日期Nov 09, 2016
CEOMr. John J. Alam, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
730.79K
+0.17%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
7.90%
Alam (John J)
7.90%
Morgan Stanley & Co. LLC
4.01%
其他
59.44%
持股股东
持股股东
占比
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
7.90%
Alam (John J)
7.90%
Morgan Stanley & Co. LLC
4.01%
其他
59.44%
股东类型
持股股东
占比
Individual Investor
31.44%
Investment Advisor/Hedge Fund
11.18%
Investment Advisor
6.53%
Research Firm
5.00%
Hedge Fund
0.85%
其他
45.00%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
117
5.12M
58.84%
-1.63M
2025Q1
117
5.20M
61.51%
-1.51M
2024Q4
109
4.40M
53.34%
-2.51M
2024Q3
92
6.43M
77.88%
-414.79K
2024Q2
78
6.37M
77.13%
+108.27K
2024Q1
52
5.40M
90.18%
+2.52M
2023Q4
54
3.10M
54.81%
+657.18K
2023Q3
54
3.32M
58.71%
+3.16M
2023Q2
46
125.98K
9.26%
-42.41K
2023Q1
54
143.15K
10.53%
-17.76K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Boger (Joshua S)
1.06M
12.15%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.92%
+863.20K
--
Mar 31, 2025
Gregoire (Sylvie L.)
730.79K
8.4%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
8.4%
+1.25K
+0.17%
Apr 24, 2025
Morgan Stanley & Co. LLC
130.60K
1.5%
+87.90K
+205.86%
Mar 31, 2025
Zavrl (Frank E.)
353.01K
4.06%
--
--
Apr 24, 2025
The Vanguard Group, Inc.
378.66K
4.35%
-4.83K
-1.26%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
321.48K
3.69%
+24.03K
+8.08%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月2日 周二
更新时间: 9月2日 周二
机构名称
占比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0%
Global X Russell 2000 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
ProShares UltraPro Russell2000
占比0%
iShares Health Innovation Active ETF
占比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
占比0%
iShares Russell 2000 ETF
占比0%
ProShares Hedge Replication ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
公告日期
类型
比率
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
